EPA:SAN

Sanofi Stock Forecast, Price & News

€86.52
-1.07 (-1.22 %)
(As of 07/29/2021 12:00 AM ET)
Add
Compare
Today's Range
€85.98
€89.48
50-Day Range
€85.33
€89.11
52-Week Range
€63.09
€92.97
Volume2.38 million shs
Average Volume3.05 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SAN News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.


Sanofi logo

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.32 out of 5 stars

Analyst Opinion: 3.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Sanofi (EPA:SAN) Frequently Asked Questions

Is Sanofi a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sanofi stock.
View analyst ratings for Sanofi
or view top-rated stocks.

What stocks does MarketBeat like better than Sanofi?

Wall Street analysts have given Sanofi a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sanofi wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Sanofi's stock been impacted by Coronavirus?

Sanofi's stock was trading at €79.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SAN stock has increased by 8.7% and is now trading at €86.52.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SAN?

9 Wall Street analysts have issued 12-month target prices for Sanofi's stock. Their forecasts range from €75.00 to €120.00. On average, they anticipate Sanofi's share price to reach €97.00 in the next year. This suggests a possible upside of 12.1% from the stock's current price.
View analysts' price targets for Sanofi
or view top-rated stocks among Wall Street analysts.

Who are Sanofi's key executives?

Sanofi's management team includes the following people:
  • Mr. Paul Hudson, CEO & Director (Age 54, Pay $5.63M)
  • Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 56)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Dr. Josephine Fubara, Chief Science Officer of Consumer Health Care
  • Mr. George Grofik C.F.A., CPA, CFA, Head of Investor Relations
  • Ms. Karen Linehan, Exec. VP of Legal Affairs & Gen. Counsel (Age 62)
  • Mr. Dante Beccaria, Global Compliance Officer & VP
  • Mr. Josep Catlla, Head of Communications
  • Mr. Pierre Chancel, Sr. VP of Global Diabetes and Sr. VP of Global Marketing (Age 64)

Who are some of Sanofi's key competitors?

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Skechers U.S.A. (SKX), NVIDIA (NVDA), (SNY), Intel (INTC), salesforce.com (CRM), (ECA), Bank of America (BAC), Tronox (TROX), Advanced Micro Devices (AMD) and Tesla (TSLA).

What is Sanofi's stock symbol?

Sanofi trades on the EPA under the ticker symbol "SAN."

What is Sanofi's stock price today?

One share of SAN stock can currently be purchased for approximately €86.52.

How many employees does Sanofi have?

Sanofi employs 99,412 workers across the globe.

What is Sanofi's official website?

The official website for Sanofi is en.sanofi.com.

Where are Sanofi's headquarters?

Sanofi is headquartered at 54 rue la Boetie, PARIS, 75008, France.

How can I contact Sanofi?

Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.


This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.